CD274 and cancer: Because of their role in the interferon receptor pathway, homozygous loss-of-function mutations in JAK1/2 kinases desensitised cancer cells to IFN signalling, leading to escape from IFN-induced growth inhibition, upregulation of PD-L1 and reduced antigen presentation.